[go: up one dir, main page]

WO2006022255A1 - Procédé de production de microcapsules et microcapsules, et support d'affichage magnétique les utilisant - Google Patents

Procédé de production de microcapsules et microcapsules, et support d'affichage magnétique les utilisant Download PDF

Info

Publication number
WO2006022255A1
WO2006022255A1 PCT/JP2005/015267 JP2005015267W WO2006022255A1 WO 2006022255 A1 WO2006022255 A1 WO 2006022255A1 JP 2005015267 W JP2005015267 W JP 2005015267W WO 2006022255 A1 WO2006022255 A1 WO 2006022255A1
Authority
WO
WIPO (PCT)
Prior art keywords
film
microcapsule
water
soluble polymer
microcapsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2005/015267
Other languages
English (en)
Japanese (ja)
Inventor
Taro Tozuka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pilot Corp
Original Assignee
Pilot Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pilot Corp filed Critical Pilot Corp
Publication of WO2006022255A1 publication Critical patent/WO2006022255A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles

Definitions

  • the present invention relates to a method for producing a microcapsule and a microcapsule produced thereby. More specifically, it is a method for producing a microcapsule using a complex 'coacervation method, in which a specific water-soluble high-molecular compound is allowed to coexist at the time of producing the microcapsule, and a protein as a coating.
  • the present invention relates to a microcapsule containing a specific water-soluble polymer compound.
  • the present invention further relates to a recording material such as a magnetic display medium comprising such a microcapsule.
  • microcapsules have been applied to various uses, and many proposals have been made regarding their production methods.
  • the complex coacervation method is one of the microencapsulation methods applied industrially.
  • the general complex 'coacervation method is to manufacture a microphone mouth capsule by the following process.
  • Aldehydes such as formaldehyde and dartalaldehyde are generally used as a curing agent for the microcapsule film by such a method.
  • aldehydes are effective curing agents, but it is not preferable to use them from the viewpoints of toxicity and environmental considerations.
  • Both formaldehyde and dartalaldehyde are designated as PRTR Class 1
  • formaldehyde has been suspected of being a causative agent of sick house syndrome in recent years, and is also regarded as an emission-regulated substance as a volatile organic compound (hereinafter referred to as VOC). .
  • the protein film significantly swells, resulting in distortion of the shape due to capsule volume expansion, thickening of the capsule dispersion during the manufacturing process, reduced processability after encapsulation, core material Problems such as a decrease in retention capacity may occur.
  • Patent Document 4 or 5 Techniques for preventing such swelling of the film have also been studied (Patent Document 4 or 5). These methods are examples using the salting-out method, which is a kind of orifice method or simple coacervation method, and in order to suppress the swelling of the film when the film is cured with transdaltaminase. Electrolytes such as acid salts, metaphosphates, sulfates and acetates coexist.
  • the simple coacervation method after the core material is emulsified and dispersed in a solution in which the film material is dissolved in a good solvent, the solubility of the film material is reduced by adding a poor solvent such as salt or film material. In this method, a wall film is formed around the core material.
  • the complex coacervation method is a method for forming a wall film by an electrical interaction using a polycation and polyion as a coating material, and thus is greatly different as a manufacturing method.
  • an electrolyte as described above it may be necessary to remove the electrolyte (desalting step) before using the microcapsules. That is, when the microcapsule is used as a display medium such as a magnetic display medium or a heat-sensitive recording material, when the microcapsule capsule is applied and arranged on the support, the microcapsule dispersion is applied as it is on the support. When dried, the! /, Salt, etc.
  • the complex coacervation method is not necessarily a suitable method because it needs to be added after film formation.
  • a method using a nonionic water-soluble polymer compound as an additive has been studied in order to enable the complex coacervation method to be performed in a wide pH range.
  • Patent Document 6 In this method, the suppression of swelling at the time of curing of the force film to which various nonionic water-soluble polymer compounds are added is mentioned.
  • Patent Document 7 a magnetic display medium using microcapsules has also been studied.
  • these materials use micro force capsules manufactured by conventional methods, and microcapsules containing harmful aldehydes are generally used.
  • Patent Document 1 Japanese Patent Laid-Open No. 10-249184
  • Patent Document 2 Japanese Patent Laid-Open No. 02-086741
  • Patent Document 3 Japanese Patent Laid-Open No. 05-292899
  • Patent Document 4 Japanese Patent Laid-Open No. 09-248137
  • Patent Document 5 JP 2000-079337
  • Patent Document 6 Japanese Unexamined Patent Publication No. 57-171432
  • Patent Document 7 Japanese Unexamined Patent Application Publication No. 2001-075510
  • the present invention provides a method for producing a microcapsule that does not use a highly harmful aldehyde that has been conventionally used and is suitable for a display medium such as a magnetic display medium and has a small film swelling. Is intended to provide.
  • the method for producing a microcapsule according to the present invention is such that, when producing a microcapsule having a protein film using a complex 'coacervation method, the electrical conductivity when a 10 wt% aqueous solution is used is 0.005- 1. It is characterized by the coexistence of a 2SZm water-soluble polymer compound.
  • another method for producing microcapsules according to the present invention includes the production of a microcapsule having a protein film using a complex 'core cell basing method, and polybutyl alcohol, polybutylpyrrolidone, polyethylene oxide, and the like. And a water-soluble polymer compound selected from the group consisting of a mixture thereof and a mixture thereof.
  • Another method for producing a microcapsule according to the present invention is that in the above method, the curing agent for the protein film is transdaltaminase.
  • the microcapsule according to the present invention includes a film containing a protein and a water-soluble polymer compound having an electric conductivity of 0.005 to 1.2 SZm when a 10 wt% aqueous solution is used. , Is characterized by.
  • the film has a protein, polyvinyl alcohol, polybutylpyrrolidone, polyethylene oxide, and derivatives thereof.
  • a magnetic display medium according to the present invention comprises the above microcapsule.
  • the present invention it is possible to produce a microcapsule with less shape expansion and distortion without using a highly harmful aldehyde that can cause sick house syndrome as a VOC.
  • a microcapsule with less shape expansion and distortion without using a highly harmful aldehyde that can cause sick house syndrome as a VOC.
  • the microcapsules obtained by this method it is possible to form a display medium or recording material that does not contain harmful substances and has excellent resolution.
  • the method for producing a microcapsule according to the present invention uses a complex 'coacervation method', and is characterized in that a water-soluble polymer compound is allowed to coexist when a protein film is cured (crosslinked and z-modified).
  • the method of the present invention will be described in accordance with the order of the production process as follows.
  • a core substance (oil-based substance) is dispersed in an aqueous solution containing a film substance to form an oZw emulsion in which oil droplets are dispersed in the aqueous solution.
  • the core material to be used is arbitrarily selected according to the target microcapsule.
  • examples thereof include pressure-sensitive adhesives, adhesives, and coloring materials.
  • a display medium element or the like for example, an oily substance containing fine magnetic particles of a magnetic display medium or the like as a dispersion, or a heat-sensitive recording material that changes color by heating.
  • foods, pharmaceuticals, quasi-drugs, fragrances, detergents, etc. that are immiscible with water can be used as the core substance.
  • a hydrophilic colloid having an isoelectric point as a polycation and capable of gelling is used, and a water-soluble protein is generally used. More specifically, gelatin, agar, casein, soy protein, collagen, albumin and the like can be mentioned. Of these, gelatin such as acid-treated gelatin and alkali-treated gelatin is preferred, and acid-treated gelatin is most preferred.
  • the concentration of the core material and the coating material is arbitrarily selected according to the properties and shape required for the target microcapsule.
  • the size of the core material droplet obtained by the dispersion is related to the size of the micro force capsule finally obtained.
  • the size of the microcapsules is selected according to the purpose, and the size of the emulsion droplets is substantially reflected as the particle size of the microcapsules.
  • the final size of the microcapsule is generally 0.1 to 3000 / zm, preferably ⁇ or 0.1 to 2000 111, and more preferably 0.1 to LOOO / zm. Dispersion is performed to obtain oil droplet force S according to
  • the polyone used is a force selected as necessary.
  • gum arabic, sodium carboxymethylcellulose, sodium alginate, sodium polyvinylbenzene sulfonate, polyvinyl methyl ether / maleic anhydride copolymer, etc. Is mentioned.
  • gum arabic and sodium carboxymethyl cellulose are preferably used.
  • gum arabic has a tendency to be slightly inferior in its ability to form a coacervate film against emulsions with a relatively large particle size of 100 m or more.
  • Carboxymethyl cellulose sodium has such a large particle size. U, especially preferred because it can easily form a sufficient coacervate film for the emulsion.
  • the pH of the emulsion is adjusted to an acidity, for example, pH 3 to 5, preferably 4 to 4.5.
  • an acid which does not impair the properties of the core material and the coating material.
  • organic acids such as acetic acid, succinic acid, succinic acid, oxalic acid, lactic acid and salicylic acid, and inorganic acids such as hydrochloric acid, sulfuric acid and phosphoric acid are used.
  • the emulsion on which the coacervate film is formed is subsequently cooled in order to gel the film.
  • the emulsion is cooled to 5 to 25 ° C., preferably 5 to 10 ° C. to gel the skin.
  • a hardener is subsequently mixed into the emulsion.
  • the hardener include conventionally known hardeners such as transglutaminase, formaldehyde, dartalaldehyde, amyoban, gallic acid, and tannic acid.
  • aldehydes such as formaldehyde and dartal aldehyde are not preferably used from the viewpoints of toxicity and environmental considerations. Both formaldehyde and dartal aldehyde have been designated as PRTR Class 1 Designated Chemical Substances.
  • Formaldehyde in particular, has recently been suspected of being a causative agent of sick house syndrome, and is also subject to emission control as VOC. It is positioned in
  • transglutaminase myoban, gallic acid, tannic acid, or the like.
  • Curing agents such as myoban, gallic acid, and tannic acid are also problematic in terms of toxicity and environmental load, but it is particularly preferable to use transdaltaminase from the viewpoint of insufficient curability and odor.
  • transdaltaminase is an enzyme that exhibits neutrality, specifically high pH activity in the region of pH 5-9
  • the curing reaction using transdaltaminase is pH 5-9, preferably 6-8. It is common to do this. Even when aldehydes are used as curing agents, the pH needs to be alkaline, specifically, pH 9 or higher in order to allow rapid reaction.
  • the desired microcapsules can be obtained by operations such as filtration, decantation, and drying as necessary.
  • the method for producing a microcapsule according to the present invention is characterized in that a water-soluble polymer compound is allowed to coexist in the above-described complex 'core cell basis method. Especially the core If the film is cured by adjusting the pH after forming the rubeto film, the water-soluble polymer compound is introduced into the system before the pH is changed to the desired reaction conditions. It is preferable.
  • the method in which the water-soluble polymer compound is allowed to coexist is optional.
  • the water-soluble polymer compound or an aqueous solution thereof is generally added to the system. It is.
  • the addition timing of the water-soluble polymer compound is not particularly limited. That is, it can be added in advance to an aqueous solution containing a water-soluble protein before the core substance is dispersed, or can be added at any time before and after the addition of polyion.
  • the water-soluble high molecular weight compound is added to the microcapsule dispersion having a swollen film after the addition of the curing agent, the film has a shrinking effect.
  • the water-soluble polymer compound is used after the formation of the coacervate film. It is preferable to add at the time of. In particular, when adjusting the pH after gelling the coacervate film, it is preferable to add a water-soluble polymer compound before that. If the increase in viscosity due to gel swelling exceeds the desired range, it is necessary to apply a greater shearing force to maintain the stirring conditions. If the shearing force is too strong, the capsule film may be destroyed, which is not preferable. .
  • the coacervate film has a strong tendency to swell as the pH increases
  • the water-soluble polymer compound in the present invention suppresses or reduces the swelling of the film, so that the curing conditions are adjusted.
  • transdaltaminase when transdaltaminase is used as a curing agent, it is necessary to adjust the pH to 5 to 9, preferably 6 to 8 as the curing conditions as described above. Water-soluble polymer compound Coexistence of this suppresses or reduces the swelling of the film. [0033] Note that if the water-soluble polymer compound is not added or the pH is adjusted to a neutral range with insufficient addition, the film tends to swell, but even after the film swells. The addition of a water-soluble polymer compound reduces the swelling of the film. In order to apply the production method of the present invention to an existing production process, it is easy and preferable to adopt such an addition time.
  • the water-soluble polymer compound used in the first method for producing a microcapsule according to the present invention has an electric conductivity of 0.005 to 1.2 SZm, preferably 0.0. 005-0.3SZm.
  • Examples of the water-soluble polymer compound used in the method for producing the second microcapsule according to the present invention include polybulal alcohol, polybulurpyrrolidone, polyethylene oxide, and a mixture thereof. These all suppress or reduce the swelling of the film as described above, and in the present invention, the terms polybulal alcohol, polyvinylpyrrolidone and polyethylene oxide include derivatives thereof. .
  • the water-soluble polymer compound may be a compound in which part or all of the water-soluble polymer compound is modified.
  • the water-soluble polymer compound itself can be configured to have an appropriate ionicity, interacting with the protein film, and more effective. It is preferable because it acts on (details below).
  • Examples of such an ionic group include a sulfone group, a carboxyl group, and a phosphoric acid group.
  • a sulfone group a carboxyl group
  • a phosphoric acid group a group selected from sulfonic acid and / or carboxylic acid-modified polybulal alcohol.
  • a copolymer containing the above water-soluble high molecular compound as a polymerization unit such as a copolymer having polyvinylpyrrolidone as a polymerization unit, can be used.
  • Polyvinyl pyrrolidone and derivatives thereof may act more favorably than other water-soluble polymers when using alkali-processed gelatin as a protein, and are more preferable in combination.
  • the molecular weight of these water-soluble polymer compounds is not particularly limited. Molecular weight 2000-200000, preferred ⁇ or 2000-20000, for later power! Be beaten. In general, water-soluble polymer compounds having a large molecular weight increase in viscosity when used in aqueous solutions, so care must be taken because the microcapsules are excessively sheared due to the load on the stirring power and stirring during microcapsule preparation.
  • Polyvinyl alcohol is not particularly limited to a completely saponified type or a partially saponified type, but a partially saponified type is preferred from the viewpoint of solubility in water.
  • Microcapsules of the production process of the present invention with the use of such a relatively low electrical conductivity water-soluble polymer compound, after Gerui spoon the core cell base over preparative film, the Eta [rho For example Even in the neutral region, the film swells. Such swelling of the skin film can be evaluated by the degree of swelling. In the present invention, the degree of swelling is calculated using the following method.
  • the degree of swelling (%) ⁇ (P H film volume before coating volume P H adjustment after adjustment) ZPH before adjustment of the film body volume) X 100
  • the degree of swelling measured is generally from 0% to 60%, preferably from 0% to 20%, more preferably from 0% to 10%.
  • the protein film swells in the neutral region because the increase in pH promotes the dissociation of the carboxyl group of the protein that constitutes the skin film. This is thought to be due to the fact that the amount of -ON increases and the carboxyl groups having the same charge are electrically repelled.
  • the complex 'core cell basis method is driven by the electrical ion complex of polycation and polyanion. Protein temperature does not lead to protein dissolution because the temperature in the system is below the gel point of the protein film. However, protein molecules that are charged with a ionic character cause a phenomenon such as swelling or swelling of the protein film due to electrical repulsion. Is considered to occur.
  • a first microcapsule according to the present invention comprises a protein as a film and a water-soluble polymer having an electric conductivity of 0.005 to 1.2 SZm when a 10 wt% aqueous solution is used.
  • the second microcapsule according to the present invention has a water-soluble polymer whose film is selected from the group consisting of proteins, polyalbucohol, polybulupyrrolidone, polyethylene oxide, derivatives thereof, and mixtures thereof. Compound and It contains.
  • These microcapsules contain a specific water-soluble polymer compound in the film, so that the swelling of the film is suppressed or reduced, and the distortion of the shape due to pH change is small.
  • the microcapsules according to the present invention can be used in various applications by selecting a core material and a coating material. Specific examples include adhesives, adhesives, coloring materials, foods, pharmaceutical products, quasi drugs, fragrances, and cleaning agents. In these applications, since it is necessary to consider toxicity, it is preferable not to use toxic aldehydes such as formaldehyde and dartal aldehyde as the microcapsule material. In addition, volatilization of formaldehyde, which is a VOC, and accidents caused by incorrect usage are also assumed for display media, toys, stationery, etc., which is not preferable.
  • the film does not substantially contain aldehydes having high toxicity that can cause VOCs and sick house syndrome, which are substances subject to emission control.
  • a display medium or a recording material can be formed using the micro force capsule according to the present invention.
  • an oily substance containing fine magnetic particles as a dispersion as a core substance, it can be used as an element of a magnetic display medium.
  • a thermosensitive color-changing substance that changes color by heating is used as a core material, an element of a thermosensitive recording material can be obtained.
  • a reversible feeling can be obtained by using a substance capable of color development, decoloration, and decoloration by heat, for example, a combination of an electron-accepting compound and an electron-donating color-forming compound. This can be done by forming a thermal recording material.
  • a heat-sensitive recording material using a microcapsule is already known! / For example (Patent Document 7).
  • aldehydes are often used to harden the protein film! Toxic and environmental considerations
  • the use of such aldehydes is preferable, but as a hardener that can be used in place of aldehydes, for example, only transdaltaminase described above can be used to form a coacervate film. Distortion and film volume expansion occur. For this reason, the final microcapsule has a larger volume of coating than the core material.
  • the force to arrange microcapsules on a support is usually the force between microcapsules, even if they are arranged at a high density when the film of microcapsules is expanded. A gap corresponding to the thickness of the swollen film is likely to occur, which causes a decrease in resolution and contrast.
  • the microcapsules according to the present invention have a small volume of the coating compared to the volume of the core material, it is possible to arrange the core material at a high density on the support, so that the resolution and contrast are excellent.
  • a magnetic display medium substantially free from harmful aldehydes can be provided.
  • the microcapsules according to the present invention that can be used for such applications can be produced, for example, by the above-described method for producing microcapsules.
  • the force for selecting an appropriate size according to the use of the microcapsule is generally selected such that the diameter in terms of a sphere is 0.1 to 3000 / zm, preferably 0.1 to 2000 / ⁇ ⁇ . Among these, 50 to 1000 m is preferable as a magnetic display medium, and 0.1 to LO / z m is preferable as a heat-sensitive recording material. An appropriate thickness is selected depending on the application.
  • Acetic acid (a reagent manufactured by Wako Pure Chemical Industries, Ltd.) was added to adjust the pH to 4.3 to form a coacervate film.
  • the emulsion was gradually cooled to 5 ° C while stirring to gel the film and kept stable for 30 min at 5 ° C.
  • the temperature of the system was again raised to 15 ° C., and 30 parts by weight of a 10% by weight aqueous solution of sulfonic acid-modified polybulal alcohol (Nippon Gosei Chemical Co., Ltd. Gocelan L3266) was added.
  • a 50 wt% aqueous sodium hydroxide solution was added to adjust the pH to 7.2, and 0.18 part by weight of transglutaminase (Actino TG-S manufactured by Ajinomoto Co., Inc.) was added. Stirring was continued for 16 hours while maintaining the temperature of the system at 15 ° C. to obtain a microcapsule dispersion in which the film was cured.
  • the microcapsules obtained were mononuclear microcapsules with heat resistance and no swelling of the film.
  • the final concentrations of acid-treated gelatin, sodium carboxymethylcellulose, and sulfonic acid-modified polybutyl alcohol in the aqueous solution of the system were 2.7 wt%, 0.34 wt%, and 0.91 wt%, respectively. .
  • Example 1 a micro-mouth capsule was produced in the same manner except that the water-soluble polymer compound was not added.
  • microcapsules were produced in the same manner as in Example 1 except that the water-soluble polymer compound and the pH adjustment value were changed to those shown in Table 1.
  • the degree of swelling (%) ⁇ (P H film volume before coating volume P H adjustment after adjustment) ZPH before adjustment of the film body volume) X 100
  • the film thickness is a value obtained by actually measuring a microcapsule having a core material particle size of about 500 ⁇ m with a microscope.
  • the water-soluble polymer compound used in each example is as follows.
  • Sulfonic acid-modified polyvinyl alcohol Goseilan manufactured by Nippon Synthetic Chemical Industry Co., Ltd. L- 3266
  • Carboxylic acid-modified polyvinyl alcohol Gosena Ichinole T-330, manufactured by Nippon Synthetic Chemical Industry Co., Ltd.
  • Butyl acetate Z-Buylpyrrolidone copolymer Made by ISPI Japan Ltd. PVP / VA S -630
  • Acetic acid (a reagent manufactured by Wako Pure Chemical Industries, Ltd.) was added to adjust the pH to 4.0, thereby forming a coacervate film.
  • the emulsion was gradually cooled to 5 ° C with stirring to gel the film and kept stable at 30 ° C for 5 minutes.
  • the temperature of the system was again raised to 15 ° C., and 30 parts by weight of a 10% by weight aqueous solution of polybulurpyrrolidone (PVP K 15 manufactured by ISPI Japan Co., Ltd.) was added.
  • a 50 wt% aqueous sodium hydroxide solution was added to adjust the pH to 7.3, and 0.18 part by weight of transdaltaminase (Ajinomoto Co., Ltd.
  • microcapsule dispersion having a cured film.
  • the obtained microcapsules were mononuclear microcapsules having heat resistance with little swelling of the film.
  • system alkali-treated gelatin in the aqueous solution of sodium carboxymethyl cellulose, and final concentrations are poly Bulle pyrrolidone 2.73 wt 0/0, 0.34 weight 0/0, were you and 0.91 wt% .
  • Acetic acid (a reagent manufactured by Wako Pure Chemical Industries, Ltd.) was added to adjust the pH to 4.3 to form a coacervate film.
  • the emulsion was gradually cooled to 5 ° C while stirring to gel the film and kept stable for 30 min at 5 ° C. While maintaining the temperature of the system at 5 ° C., 12 parts by weight of sulfonic acid-modified polyvinyl alcohol (Nippon Synthetic Chemical Co., Ltd. Gocelan L3266) was added and completely dissolved.
  • microcapsule dispersion After adding 3 parts by weight of 37% by weight formaldehyde solution (reagent manufactured by Wako Pure Chemical Industries, Ltd.) and stirring for 30 minutes, 50% by weight aqueous sodium hydroxide and sodium hydroxide solution was added to adjust the pH to 10.0. The temperature of the system was gradually raised to 50 ° C., held for 30 minutes, and then cooled to 20 ° C. with stirring to obtain a microcapsule dispersion in which the film was cured. The obtained microcapsules were mononuclear microcapsules having little heat-swelling and heat resistance.
  • the final concentrations of acid-treated gelatin, sodium carboxymethylcellulose, and sulfonic acid-modified polybutyl alcohol in the aqueous solution of the system were 2.86 wt%, 0.36 wt%, and 3.8 wt%, respectively. .
  • Comparative Examples 5-6 Microcapsules were produced in the same manner as in Examples 10 and 11 except that the water-soluble polymer compound was not added and the pH adjustment value was as shown in Table 2.
  • a plastic dispersion in which an oil-based plastic liquid composed mainly of fine magnetic particles and isoparaffin (Esoso M, manufactured by Ethso Chemical Co., Ltd.) is used as a core material, and the system temperature is kept at 40 ° C.
  • the SZOZW emulsion was emulsified and dispersed in an aqueous solution that was uniformly mixed with 90 parts by weight of an acid-treated gelatin aqueous solution (AP200 manufactured by Futsubi Co., Ltd.) and 120 parts by weight of 40 ° C hot water (ion-exchanged water). Formed.
  • the temperature of the system was again raised to 15 ° C., and 30 parts by weight of a 10% by weight aqueous solution of sulfonic acid-modified polybulal alcohol (Goseiran L3266, manufactured by Nippon Synthetic Chemical Industry Co., Ltd.) was added. A 50 wt% aqueous sodium hydroxide solution was added to adjust the pH to 6.8, and 0.18 parts by weight of transglutaminase (Actino TG-S manufactured by Ajinomoto Co., Inc.) was added. Stirring was continued for 16 hours while maintaining the temperature of the system at 15 ° C to obtain a microcapsule dispersion liquid with a cured film.
  • sulfonic acid-modified polybulal alcohol Goseiran L3266, manufactured by Nippon Synthetic Chemical Industry Co., Ltd.
  • a 50 wt% aqueous sodium hydroxide solution was added to adjust the pH to 6.8, and 0.18 parts by weight of transglutaminase (Actino TG
  • the obtained microcapsule dispersion was coated with a 125 ⁇ m thick PET film as a support to form a magnetic display medium.
  • the obtained magnetic display medium had sufficient resolution.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)

Abstract

La présente invention concerne un procédé de production de microcapsules, pouvant produire des microcapsules ne présentant pas une tendance excessive à former une pellicule importante sans utiliser d'aldéhyde, ainsi que des microcapsules produites selon le procédé. Ce procédé de production de microcapsules est un procédé de production de microcapsules ayant une pellicule de protéine utilisant un procédé de coacervation complexe et est caractérisé en ce que, pendant le traitement d'une pellicule coacervée, un composé polymère hydrosoluble ayant une conductivité électrique de 0,005 à 1,2 S/m sous forme de solution aqueuse à 10 % en poids, ou un composé polymère hydrosoluble sélectionné dans le groupe comprenant l'alcool polyvinylique, la polyvinylpyrrolidone, le polyéthylène oxyde et leurs mélanges peut également coexister. Les microcapsules ainsi produites contiennent l'un quelconque des composés polymères hydrosolubles ci-dessus mentionnés dans leur partie formant pellicule. Ces microcapsules sont utiles, par exemple, pour des supports d'affichage magnétiques.
PCT/JP2005/015267 2004-08-26 2005-08-23 Procédé de production de microcapsules et microcapsules, et support d'affichage magnétique les utilisant Ceased WO2006022255A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004247309A JP4954454B2 (ja) 2004-08-26 2004-08-26 マイクロカプセルの製造法ならびにマイクロカプセル及びそれを用いた磁気表示媒体
JP2004-247309 2004-08-26

Publications (1)

Publication Number Publication Date
WO2006022255A1 true WO2006022255A1 (fr) 2006-03-02

Family

ID=35967467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/015267 Ceased WO2006022255A1 (fr) 2004-08-26 2005-08-23 Procédé de production de microcapsules et microcapsules, et support d'affichage magnétique les utilisant

Country Status (2)

Country Link
JP (1) JP4954454B2 (fr)
WO (1) WO2006022255A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710224B1 (pt) * 2006-04-04 2016-07-26 Firmenich & Cie método para preparar microcápsulas por coacervação
CN111408325B (zh) * 2019-01-07 2022-03-15 长春理工大学 一种磁性微胶囊的制法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57171432A (en) * 1981-04-10 1982-10-22 Shionogi & Co Ltd Micro-encapsulating method
JPH01299639A (ja) * 1988-05-30 1989-12-04 Sekisui Fine Chem Kk マイクロカプセル及びその製造方法
JPH10249184A (ja) * 1997-01-31 1998-09-22 Givaudan Roure Internatl Sa タンパク質カプセル化油粒子
JP2001075510A (ja) * 1999-07-05 2001-03-23 Itochu Corp マイクロカプセル磁気表示シート

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05292899A (ja) * 1991-06-24 1993-11-09 Ajinomoto Co Inc マイクロカプセルの製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57171432A (en) * 1981-04-10 1982-10-22 Shionogi & Co Ltd Micro-encapsulating method
JPH01299639A (ja) * 1988-05-30 1989-12-04 Sekisui Fine Chem Kk マイクロカプセル及びその製造方法
JPH10249184A (ja) * 1997-01-31 1998-09-22 Givaudan Roure Internatl Sa タンパク質カプセル化油粒子
JP2001075510A (ja) * 1999-07-05 2001-03-23 Itochu Corp マイクロカプセル磁気表示シート

Also Published As

Publication number Publication date
JP4954454B2 (ja) 2012-06-13
JP2006061826A (ja) 2006-03-09

Similar Documents

Publication Publication Date Title
CN110461462B (zh) 制备具有改善的滞留性能的胶囊的方法和由该方法得到的胶囊
Bysell et al. Microgels and microcapsules in peptide and protein drug delivery
FI59362C (fi) Sensibiliserat ark foer ett tryckkaensligt kopieringssystem och foerfarande foer framstaellning av detsamma
Roy et al. Influence of process parameters on microcapsule formation from chitosan—Type B gelatin complex coacervates
KR20030048122A (ko) 코어-쉘 입자 및 이의 제조방법
US20120288479A1 (en) Cross-Linked Polymer Based Hydrogel Material Compositions, Methods and Applications
Madan Microencapsulation I. Phase separation or coacervation
Picchio et al. pH-responsive casein-based films and their application as functional coatings in solid dosage formulations
JPH11228850A (ja) 高分子ゲル組成物、その製造方法及びそれを用いた光学素子
Kitayama et al. pH-Responsive Capsule Polymer Particles Prepared by Interfacial Photo-Cross-Linking: Effect of the Alkyl Chain Length of the pH-Responsive Monomer
WO2006022255A1 (fr) Procédé de production de microcapsules et microcapsules, et support d'affichage magnétique les utilisant
JP5172093B2 (ja) マイクロカプセルの製造法ならびにマイクロカプセル及びそれを用いた表示媒体
JP2000256590A (ja) インク組成物
CN110062769A (zh) 制备可控尺寸的微粒和微胶囊的方法
Lee et al. Biphasic release characteristics of dual drug-loaded alginate beads
Quaglia et al. Microspheres Made of Poly (ε‐caprolactone)‐Based Amphiphilic Copolymers: Potential in Sustained Delivery of Proteins
KR20080036120A (ko) 장벽 형성 방법
JP2006255536A (ja) ｐＨ応答性マイクロカプセルの調製方法
Belthle et al. Aqueous microgels with engineered hydrophobic nano-domains
JPS63256127A (ja) 疎水性油のマイクロカプセル化方法、それにより得られたマイクロカプセル、およびその利用方法
Dolya et al. Catalysis by thermoresponsive polymers
JP5057501B2 (ja) マイクロカプセルの製造法ならびにマイクロカプセル及びそれを用いた表示媒体
JP4896410B2 (ja) マイクロカプセルの製造法ならびにマイクロカプセル及びそれを用いた表示媒体
JP2007222786A (ja) マイクロカプセルおよびその製造法ならびにマイクロカプセルを具備してなる表示媒体
Jana et al. Chitosan-Based Interpenetrating Polymer Networks: Drug Delivery Application

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP